一段话概述
Arbor mines genetic data from microbes for editing proteins nobody has characterised yet, then engineers the promising ones into therapies. Its lead programme targets a rare metabolic disease that causes kidney failure in children.
Arbor Biotechnologies was founded in 2016 by Feng Zhang, David Scott, David Walt and Winston Yan. It combines computational discovery of novel CRISPR-associated proteins with protein engineering. Its lead clinical programme, ABO-101, targets primary hyperoxaluria type 1.
Sources
- Arbor Biotechnologies
Arbor Biotechnologies ↗
非投资建议
本档案为依据公开披露信息汇编的教育性资料，不构成对任何证券的买入、卖出或持有建议，也不代表对该公司前景的任何判断。生物技术领域具有高度投机性，大多数临床项目最终以失败告终。
完整免责声明 →